Misplaced Pages

Olopatadine/mometasone, sold under the brand name Ryaltris, is a fixed-dose combination medication for the treatment of allergic rhinitis and rhinoconjunctivitis in adults and adolescents twelve years of age and older. It contains olopatadine hydrochloride and mometasone furoate monohydrate. It is sprayed into the nose.

Common side effects include an unpleasant taste (dysgeusia).

It was approved for medical use in Australia in December 2019, and in the United States in January 2022.

References

1. ^ "Ryaltris (olopatadine hydrochloride and mometasone furoate monohydrate) Nasal Spray". Retrieved 25 July 2020.
2. ^ "Ryaltris- olopatadine hydrochloride and mometasone furoate spray, metered". DailyMed. 9 January 2022. Retrieved 20 June 2022.
3. Chen R, Zheng D, Zhang Y, Sima G (September 2021). "Efficacy and safety of twice-daily olopatadine-mometasone combination nasal spray (GSP301) in the treatment of allergic rhinitis: a systematic review and meta-analysis". European Archives of Oto-rhino-laryngology. 279 (4): 1691–1699. doi:10.1007/s00405-021-07085-w. PMID 34591150. S2CID 238223252.
4. "Ryaltris nasal spray approved in Australia". OINDPnews. 20 December 2019. Retrieved 25 July 2020.

External links

• "Olopatadine". Drug Information Portal. U.S. National Library of Medicine.
• "Mometasone furoate". Drug Information Portal. U.S. National Library of Medicine.
• Clinical trial number NCT02631551 for "Efficacy and Safety of Fixed Dose Combination GSP 301 Nasal Spray (NS) in the Treatment of Seasonal Allergic Rhinitis (SAR) (GSP 301-301)" at ClinicalTrials.gov
• Clinical trial number NCT02870205 for "Efficacy and Safety of GSP 301 Nasal Spray in the Treatment of Seasonal Allergic Rhinitis (SAR) (GSP 301-304)" at ClinicalTrials.gov

• Medicine

This drug article relating to the respiratory system is a stub. You can help Misplaced Pages by expanding it.

• v
• t
• e

• Drugs not assigned an ATC code
• Combination drugs
• Respiratory system drug stubs